Andrew Duke - Fusion Pharm Ex VP
| FSPM Stock | USD 0.0001 0.00 0.000003% |
Insider
Andrew Duke is Ex VP of Fusion Pharm
| Age | 69 |
| Address | 5850 East 58th Avenue, Commerce City, CO, United States, 80022 |
| Phone | 720-458-0686 |
| Web | https://www.fusionpharminc.com |
Fusion Pharm Management Efficiency
The company has return on total asset (ROA) of (1.3769) % which means that it has lost $1.3769 on every $100 spent on assets. This is way below average. Fusion Pharm's management efficiency ratios could be used to measure how well Fusion Pharm manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Fusion Pharm's Other Assets are very stable compared to the past year. As of the 30th of January 2025, Intangible Assets is likely to grow to 102.64, while Total Assets are likely to drop 3,450.Management Performance
| Return On Asset | -1.38 |
Fusion Pharm Leadership Team
Elected by the shareholders, the Fusion Pharm's board of directors comprises two types of representatives: Fusion Pharm inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fusion. The board's role is to monitor Fusion Pharm's management team and ensure that shareholders' interests are well served. Fusion Pharm's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fusion Pharm's outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Sears, Chief Officer | ||
| Andrew Duke, Ex VP |
Fusion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fusion Pharm a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.38 | ||||
| Profit Margin | (1.11) % | ||||
| Operating Margin | (1.24) % | ||||
| Current Valuation | 294.4 K | ||||
| Shares Outstanding | 10.59 M | ||||
| Price To Earning | (0.07) X | ||||
| Price To Sales | 0 X | ||||
| Revenue | 594.4 K | ||||
| Gross Profit | 67.01 K | ||||
| Net Income | (42.08 K) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharm guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Consumer Staples Distribution & Retail space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion Pharm. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 0.133 | Return On Assets (1.38) |
The market value of Fusion Pharm is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharm's value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion Pharm's market value can be influenced by many factors that don't directly affect Fusion Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.